Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A preparing method of drug carrying nanoparticles for targeted treatment of malignant lymphoma

A malignant lymphoma, drug-loaded nanotechnology, applied in the field of preparation of drug-loaded nanoparticles, can solve the problems of short half-life, multi-drug resistance of tumor cells, etc., to reduce damage, improve bioavailability and tumor targeting efficiency effect

Inactive Publication Date: 2019-01-01
SOUTH CHINA UNIV OF TECH
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Doxorubicin is a broad-spectrum antitumor antibiotic drug, which is widely used and has good curative effect on a variety of tumors. However, due to its short half-life, it is cytotoxic to normal tissues and easily causes multidrug resistance of tumor cells. medicinal properties, so there are still certain limitations in clinical use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A preparing method of drug carrying nanoparticles for targeted treatment of malignant lymphoma
  • A preparing method of drug carrying nanoparticles for targeted treatment of malignant lymphoma
  • A preparing method of drug carrying nanoparticles for targeted treatment of malignant lymphoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] 1. Weigh 0.2g of PEG-PLGA-COOH and dissolve it in 4-5ml of dichloromethane.

[0036] 2. Weigh 0.02g of doxorubicin hydrochloride and dissolve it in 2ml of DMSO, add 40mg of triethylamine, stir for 4-12 hours, dehydrochloride doxorubicin hydrochloride, then add it to the liquid obtained in step 1, and ultrasonicate for 5 minutes to make Doxorubicin is uniformly dispersed in the liquid.

[0037] 3. Precisely weigh 0.5 g of sodium cholate and dissolve it in 50 ml of deionized water to prepare a 1% sodium cholate solution; prepare a 0.5% sodium cholate solution in the same way.

[0038] 4. Mix the liquid obtained in step 2 into the solution (20mL) prepared in step 1, and use an ultrasonic instrument at 120W to sonicate for 1 minute, so that the drug is evenly dispersed in the organic phase.

[0039] 5. Use a 5ml syringe to draw the solution in step 4, and add it dropwise to the 1% sodium cholate solution under the condition of ultrasound (180W, 5min) of the cell disruptor....

Embodiment 2

[0044] 1. Weigh 0.2g of PEG-PLGA and dissolve it in 4-5ml of dichloromethane.

[0045] 2. Weigh 0.02g of doxorubicin hydrochloride and dissolve it in 2ml of DMSO, add 40mg of triethylamine, stir for 4-12 hours, dehydrochloride doxorubicin hydrochloride, then add it to the liquid obtained in step 1, and ultrasonicate for 5 minutes to make Doxorubicin is uniformly dispersed in the liquid.

[0046] 3. Precisely weigh 0.5 g of sodium cholate and dissolve it in 50 ml of deionized water to prepare a 1% sodium cholate solution; prepare a 0.5% sodium cholate solution in the same way.

[0047] 4. Mix the liquid obtained in step 2 into the solution (20 mL) prepared in step 1, and use an ultrasonic instrument at 80 W for 1 minute to disperse the drug evenly in the organic phase.

[0048] 5. Use a 5ml syringe to draw the solution in step 4, and add it dropwise to the 1% sodium cholate solution under the condition of ultrasound (180W, 5min) of the cell disruptor. It can be observed that the...

Embodiment 3

[0053] 1. Weigh 0.2g of PEG-PLGA and dissolve it in 4-5ml of dichloromethane.

[0054] 2. Weigh 0.02g of doxorubicin hydrochloride and dissolve it in 2ml of DMSO, add 40mg of triethylamine, stir for 4-12 hours, dehydrochloride doxorubicin hydrochloride, then add it to the liquid obtained in step 1, and ultrasonicate for 5 minutes to make Doxorubicin is uniformly dispersed in the liquid.

[0055] 3. Precisely weigh 0.5 g of sodium cholate and dissolve it in 50 ml of deionized water to prepare a 1% sodium cholate solution; prepare a 0.5% sodium cholate solution in the same way.

[0056] 4. Mix the liquid obtained in step 2 into the solution (20mL) prepared in step 1, and use an ultrasonic instrument at 300W to sonicate for 1 minute, so that the drug is evenly dispersed in the organic phase.

[0057] 5. Use a 5ml syringe to draw the solution in step 4, and add it dropwise to the 1% sodium cholate solution under the condition of ultrasound (180W, 5min) of the cell disruptor. It c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A preparing method of drug carrying nanoparticles for targeted treatment of malignant lymphoma is disclosed. An amphoteric polymer PEG-PLGA having good biocompatibility is adopted as a carrier center,a hydrophobic segment covers and carries a hydrophobic drug that is adriamycin (DOX), and carboxyl exposed at the outer end is activated through a chemical reaction and is boned with a nucleic acid aptamer having amino. The drug carrying nanoparticles are rapidly delivered to a tumor position by utilizing the targeting function of the nucleic acid aptamer, and the drug is released slowly by utilizing the sustained release function of the PEG-PLGA nanoparticles, thus achieving long-acting efficient treatment of the malignant lymphoma, and reducing side effects caused by common therapies such as chemotherapy.

Description

technical field [0001] The invention belongs to the technical field of biochemical medicine. The invention relates to a preparation method of drug-loaded nanoparticles for targeted treatment of malignant lymphoma. Background technique [0002] Specific nucleic acid aptamer (Aptamer) is a small molecule ligand (usually 20-50 bases) composed of oligopeptide nucleotides, which can specifically bind to the corresponding target. Compared with antibodies, it has the following advantages: 1. Low molecular weight (8-25kDa), penetrates tissues more quickly and reaches the target position; 2. Non-immunogenic, not easily recognized by the immune system; 3. Has thermal stability; 4. It can be synthesized and modified in large quantities; 5. Compared with the preparation cost of antibodies, the preparation cost of nucleic acid aptamers is relatively much lower. [0003] CD30 molecule is a specific marker of malignant lymphoma, which is widely expressed on the surface of Hodgkin's lymph...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K47/69A61K47/54A61K31/704A61P35/00
CPCA61K31/704A61K47/549A61K47/6937A61P35/00
Inventor 魏坤罗逍牛雪明万淑倩莫灿龙
Owner SOUTH CHINA UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com